Autocrine regulation of tumor cell repopulation by Hsp70-HMGB1 alarmin complex.
Alarmins
HMGB1
Hsp70
Protein complex
Tumor relapse
Journal
Journal of experimental & clinical cancer research : CR
ISSN: 1756-9966
Titre abrégé: J Exp Clin Cancer Res
Pays: England
ID NLM: 8308647
Informations de publication
Date de publication:
25 Oct 2023
25 Oct 2023
Historique:
received:
08
05
2023
accepted:
08
10
2023
medline:
27
10
2023
pubmed:
26
10
2023
entrez:
26
10
2023
Statut:
epublish
Résumé
Cancer recurrence is regulated by a variety of factors, among which is the material of dying tumor cells; it is suggested that remaining after anti-cancer therapy tumor cells receive a signal from proteins called damage-associated molecular patterns (DAMPs), one of which is heat shock protein 70 (Hsp70). Two models of tumor repopulation were employed, based on minimal population of cancer cells and application of conditioned medium (CM). To deplete the CMs of Hsp70 affinity chromatography on ATP-agarose and immunoprecipitation were used. Cell proliferation and the dynamics of cell growth were measured using MTT assay and xCELLigence technology; cell growth markers were estimated using qPCR and with the aid of ELISA for prostaglandin E detection. Immunoprecipitation followed by mass-spectrometry was employed to identify Hsp70-binding proteins and protein-protein interaction assays were developed to reveal the above protein complexes. It was found that CM of dying tumor cells contains tumor regrowth-initiating factors and the removal of one of them, Hsp70, caused a reduction in the relapse-activating capacity. The pull out of Hsp70 alone using ATP-agarose had no effect on repopulation, while the immunodepletion of Hsp70 dramatically reduced its repopulation activity. Using proteomic and immunochemical approaches, we showed that Hsp70 in conditioned medium binds and binds another abundant alarmin, the High Mobility Group B1 (HMGB1) protein; the complex is formed in tumor cells treated with anti-cancer drugs, persists in the cytosol and is further released from dying tumor cells. Recurrence-activating power of Hsp70-HMGB1 complex was proved by the enhanced expression of proliferation markers, Ki67, Aurka and MCM-10 as well as by increase of prostaglandin E production and autophagy activation. Accordingly, dissociating the complex with Hsp70 chaperone inhibitors significantly inhibited the pro-growth effects of the above complex, in both in vitro and in vivo tumor relapse models. These data led us to suggest that the abundance of the Hsp70-HMGB1 complex in the extracellular matrix may serve as a novel marker of relapse state in cancer patients, while specific targeting of the complex may be promising in the treatment of cancers with a high risk of recurrence.
Sections du résumé
BACKGROUND
BACKGROUND
Cancer recurrence is regulated by a variety of factors, among which is the material of dying tumor cells; it is suggested that remaining after anti-cancer therapy tumor cells receive a signal from proteins called damage-associated molecular patterns (DAMPs), one of which is heat shock protein 70 (Hsp70).
METHODS
METHODS
Two models of tumor repopulation were employed, based on minimal population of cancer cells and application of conditioned medium (CM). To deplete the CMs of Hsp70 affinity chromatography on ATP-agarose and immunoprecipitation were used. Cell proliferation and the dynamics of cell growth were measured using MTT assay and xCELLigence technology; cell growth markers were estimated using qPCR and with the aid of ELISA for prostaglandin E detection. Immunoprecipitation followed by mass-spectrometry was employed to identify Hsp70-binding proteins and protein-protein interaction assays were developed to reveal the above protein complexes.
RESULTS
RESULTS
It was found that CM of dying tumor cells contains tumor regrowth-initiating factors and the removal of one of them, Hsp70, caused a reduction in the relapse-activating capacity. The pull out of Hsp70 alone using ATP-agarose had no effect on repopulation, while the immunodepletion of Hsp70 dramatically reduced its repopulation activity. Using proteomic and immunochemical approaches, we showed that Hsp70 in conditioned medium binds and binds another abundant alarmin, the High Mobility Group B1 (HMGB1) protein; the complex is formed in tumor cells treated with anti-cancer drugs, persists in the cytosol and is further released from dying tumor cells. Recurrence-activating power of Hsp70-HMGB1 complex was proved by the enhanced expression of proliferation markers, Ki67, Aurka and MCM-10 as well as by increase of prostaglandin E production and autophagy activation. Accordingly, dissociating the complex with Hsp70 chaperone inhibitors significantly inhibited the pro-growth effects of the above complex, in both in vitro and in vivo tumor relapse models.
CONCLUSIONS
CONCLUSIONS
These data led us to suggest that the abundance of the Hsp70-HMGB1 complex in the extracellular matrix may serve as a novel marker of relapse state in cancer patients, while specific targeting of the complex may be promising in the treatment of cancers with a high risk of recurrence.
Identifiants
pubmed: 37880798
doi: 10.1186/s13046-023-02857-0
pii: 10.1186/s13046-023-02857-0
pmc: PMC10598926
doi:
Substances chimiques
HSP70 Heat-Shock Proteins
0
Alarmins
0
HMGB1 Protein
0
Culture Media, Conditioned
0
Prostaglandins
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
279Subventions
Organisme : Russian Science Foundation
ID : 19-74-20161
Organisme : Ministry of Science and High Education (RF)
ID : # 075-15-2020-773
Informations de copyright
© 2023. Italian National Cancer Institute ‘Regina Elena’.
Références
Basu S, Dong Y, Kumar R, Jeter C, Tang DG. Slow-cycling (dormant) cancer cells in therapy resistance, cancer relapse and Metastasis. Semin Cancer Biol. 2022;78:90–103. https://doi.org/10.1016/j.semcancer.221.04.021 .
doi: 10.1016/j.semcancer.221.04.021
pubmed: 33979674
Vallette FM, Olivier C, Lézot F, Oliver L, Cochonneau D, Lalier L, Cartron PF, Heymann D. Dormant, quiescent, tolerant and persister cells: four synonyms for the same target in cancer. Biochem Pharmacol. 2019;162:169–76. https://doi.org/10.1016/j.bcp.2018.11.004 .
doi: 10.1016/j.bcp.2018.11.004
pubmed: 30414937
Alhasan B, Mikeladze M, Guzhova I, Margulis B. Autophagy, molecular chaperones, and unfolded protein response as promoters of Tumor recurrence. Cancer Metastasis Rev. 2023;42:217–54. https://doi.org/10.1007/s10555-023-10085-3 .
doi: 10.1007/s10555-023-10085-3
pubmed: 36723697
Oka T, Higa T, Sugahara O, Koga D, Nakayama S, Nakayama KI. Ablation of p57 + Quiescent Cancer Stem Cells Suppresses Recurrence After Chemotherapy of Intestinal Tumors. Cancer Res 2023;CAN-22-2578. https://doi.org/10.1158/0008-5472.CAN-22-2578 .
Haak VM, Huang S, Panigrahy D. Debris-stimulated Tumor growth: a Pandora’s box? Cancer Metastasis Rev. 2021;40:791–801. https://doi.org/10.1007/s10555-021-09998-8 .
doi: 10.1007/s10555-021-09998-8
pubmed: 34665387
pmcid: 8524220
Ahmed A, Tait SWG. Targeting immunogenic cell death in cancer. Mol Oncol. 2020;14:2994–3006. https://doi.org/10.1002/1878-0261.12851 .
doi: 10.1002/1878-0261.12851
pubmed: 33179413
pmcid: 7718954
Xue J, Suarez JS, Minaai M, Li S, Gaudino G, Pass HI, Carbone M, Yang H. HMGB1 as a therapeutic target in Disease. J Cell Physiol. 2021;236:3406–19. https://doi.org/10.1002/jcp.30125 .
doi: 10.1002/jcp.30125
pubmed: 33107103
Boudesco C, Cause S, Jego G, Garrido C. Hsp70: a Cancer Target Inside and outside the cell. Methods Mol Biol. 2018;1709:371–96. https://doi.org/10.1007/978-1-4939-7477-1_27 .
doi: 10.1007/978-1-4939-7477-1_27
pubmed: 29177673
Shevtsov MA, Pozdnyakov AV, Mikhrina AL, Yakovleva LY, Nikolaev BP, Dobrodumov AV, et al. Effective immunotherapy of rat glioblastoma with prolonged intratumoral delivery of exogenous heat shock protein Hsp70. Int J Cancer. 2014;135:2118–28. https://doi.org/10.1002/ijc.28858 .
doi: 10.1002/ijc.28858
pubmed: 24691976
Komarova EY, Suezov RV, Nikotina AD, Aksenov ND, Garaeva LA, Shtam TA, et al. Hsp70-containing extracellular vesicles are capable of activating of adaptive immunity in models of mouse Melanoma and colon carcinoma. Sci Rep. 2021;11:21314. https://doi.org/10.1038/s41598-021-00734-4 .
doi: 10.1038/s41598-021-00734-4
pubmed: 34716378
pmcid: 8556270
Mączyńska J, Da Pieve C, Burley TA, Raes F, Shah A, Saczko J, Harrington KJ. Kramer-Marek G Immunomodulatory activity of IR700-labelled affibody targeting HER2. Cell Death Dis. 2020;11:886. https://doi.org/10.1038/s41419-020-03077-6 .
doi: 10.1038/s41419-020-03077-6
pubmed: 33082328
pmcid: 7576828
Sulciner ML, Serhan CN, Gilligan MM, Mudge DK, Chang J, Gartung A, et al. Resolvins suppress Tumor growth and enhance Welch cancer therapy. J Exp Med. 2018;215:115–40. https://doi.org/10.1084/jem.20170681 .
doi: 10.1084/jem.20170681
pubmed: 29191914
pmcid: 5748851
Komarova EY, Marchenko LV, Zhakhov AV, Nikotina AD, Aksenov ND, Suezov RV, et al. Extracellular Hsp70 reduces the Pro-tumor Capacity of Monocytes/Macrophages co-cultivated with Cancer cells. Int J Mol Sci. 2019;21:59. https://doi.org/10.3390/ijms21010059 .
doi: 10.3390/ijms21010059
pubmed: 31861801
pmcid: 6982218
Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods. 1983;65:55–63. https://doi.org/10.1016/0022-1759(83)90303-4 .
doi: 10.1016/0022-1759(83)90303-4
pubmed: 6606682
Chevallet M, Diemer H, Van Dorssealer A, Villiers C, Rabilloud T. Toward a better analysis of secreted proteins: the example of the myeloid cells secretome. Proteomics. 2007;7:1757–70. https://doi.org/10.1002/pmic.200601024 .
doi: 10.1002/pmic.200601024
pubmed: 17464941
pmcid: 2386146
Lauber K, Herrmann M. Tumor biology: with a little help from my dying friends. Curr Biol. 2015;25:R198–201. https://doi.org/10.1016/j.cub.2015.01.040 .
doi: 10.1016/j.cub.2015.01.040
pubmed: 25734269
Huang Q, Li F, Liu X, Li W, Shi W, Liu FF, et al. Caspase-3-mediated stimulation of Tumor cell repopulation during cancer radiotherapy. Nat Med. 2011;17:860–6. https://doi.org/10.1038/nm.2385 .
doi: 10.1038/nm.2385
pubmed: 21725296
pmcid: 3132290
Castellone MD, Teramoto H, Williams BO, Druey KM, Gutkind JS. Prostaglandin E2 promotes colon Cancer cell growth through a Gs-axin-beta-catenin signaling axis. Science. 2005;310:1504–10. https://doi.org/10.1126/science.1116221 .
doi: 10.1126/science.1116221
pubmed: 16293724
Mishra V, Jain S, Anand V, Malhotra P, Tejwani N, Kapoor G. Impact of minimal residual Disease on relapse in childhood acute lymphoblastic Leukemia: lessons learnt from a tertiary cancer center in India. Pediatr Hematol Oncol. 2023;17:1–12. https://doi.org/10.1080/08880018.2023.2186553 .
doi: 10.1080/08880018.2023.2186553
Birmpilis AI, Paschalis A, Mourkakis A, Christodoulou P, Kostopoulos IV, Antimissari E. Immunogenic cell death, DAMPs and Prothymosin α as a putative Anticancer Immune Response Biomarker. Cells. 2022;11:1415. https://doi.org/10.3390/cells11091415 .
doi: 10.3390/cells11091415
pubmed: 35563721
pmcid: 9102069
Gehrmann M, Pfister K, Hutzler P, Gastpar R, Margulis B, Multhoff G. Effects of antineoplastic agents on cytoplasmic and membrane-bound heat shock protein 70 (Hsp70) levels. Biol Chem. 2002;383:1715–25. https://doi.org/10.1515/BC.2002.192 .
doi: 10.1515/BC.2002.192
pubmed: 12530536
Du R, Huang C, Liu K, Li X, Dong Z. Targeting AURKA in Cancer: molecular mechanisms and opportunities for Cancer therapy. Mol Cancer. 2021;20:15. https://doi.org/10.1186/s12943-020-01305-3 .
doi: 10.1186/s12943-020-01305-3
pubmed: 33451333
pmcid: 7809767
Willems E, Lombard A, Dedobbeleer M, Goffart N, Rogister B. The unexpected roles of Aurora A kinase in Gliobastoma Recurrences. Target Oncol. 2017;12:11–8. https://doi.org/10.1007/s11523-016-0457-2 .
doi: 10.1007/s11523-016-0457-2
pubmed: 27573024
Scholzen T, Gerdes J. The Ki-67 protein: from the known and the unknown. J Cell Physiol. 2000;182(3):311–22. https://doi.org/10.1002/(SICI)1097-4652(200003)182:3<311::AID-JCP1>3.0.CO;2-9 .
doi: 10.1002/(SICI)1097-4652(200003)182:3<311::AID-JCP1>3.0.CO;2-9
pubmed: 10653597
Wang M, Xie S, Yuan W, Xie T, Jamal M, Huang J, Yin Q, Song H, Zhang Q. Minichromosome maintenance protein 10 as a marker for proliferation and prognosis in Lung cancer. Int J Oncol. 2019;55:1349–60. https://doi.org/10.3892/ijo.2019.4899 .
doi: 10.3892/ijo.2019.4899
pubmed: 31638210
Shevtsov MA, Komarova EY, Meshalkina DA, Bychkova NV, Aksenov ND, Abkin SV, et al. Exogenously delivered heat shock protein 70 displaces its endogenous analogue and sensitizes cancer cells to lymphocytes-mediated cytotoxicity. Oncotarget. 2014;5:3101–14. https://doi.org/10.18632/oncotarget.1820 .
doi: 10.18632/oncotarget.1820
pubmed: 24797019
pmcid: 4102795
Raucci A, Di Maggio S, Scavello F, D’Ambrosio A, Bianchi ME, Capogrossi MC. The Janus face of HMGB1 in Heart Disease: a necessary update. Cell Mol Life Sci. 2019;76:211–29. https://doi.org/10.1007/s00018-018-2930-9 .
doi: 10.1007/s00018-018-2930-9
pubmed: 30306212
Kim ID, Shin JH, Lee HK, Jin YC, Lee JK. Intranasal delivery of HMGB1-binding heptamer peptide confers a robust neuroprotection in the postischemic brain. Neurosci Lett. 2012;525:179–83. https://doi.org/10.1016/j.neulet.2012.07.040 .
doi: 10.1016/j.neulet.2012.07.040
pubmed: 22877697
Ma H, Zheng S, Zhang X, Gong T, et al. High mobility group box 1 promotes radioresistance in esophageal squamous cell carcinoma cell lines by modulating autophagy. Cell Death Dis. 2019;10:136. https://doi.org/10.1038/s41419-019-1355-1 .
doi: 10.1038/s41419-019-1355-1
pubmed: 30755598
pmcid: 6372718
Tang D, Kang R, Livesey KM, Cheh CW, Farkas A, Loughran P, et al. Endogenous HMGB1 regulates autophagy. J Cell Biol. 2010;190:881–92. https://doi.org/10.1083/jcb.200911078 .
doi: 10.1083/jcb.200911078
pubmed: 20819940
pmcid: 2935581
Chen X, Wang P, Guo F, Wang X, Xu J, Yuan D, et al. Autophagy enhanced the radioresistance of non-small cell Lung cancer by regulating ROS level under hypoxia condition. Int J Radiat Biol. 2017;93:764–70. https://doi.org/10.1080/09553002.2017.1325025 .
doi: 10.1080/09553002.2017.1325025
pubmed: 28463025
Budina-Kolomets A, Balaburski GM, Bondar A, Beeharry N, Yen T, Murphy ME. Comparison of the activity of three different HSP70 inhibitors on apoptosis, cell cycle arrest, autophagy inhibition, and HSP90 inhibition. Cancer Biol Ther. 2014;15:194–9. https://doi.org/10.4161/cbt.26720 .
doi: 10.4161/cbt.26720
pubmed: 24100579
Yaglom JA, Wang Y, Li A, Li Z, Monti S, Alexandrov I, Lu X, Sherman MY. Cancer cell responses to Hsp70 inhibitor JG-98: comparison with Hsp90 inhibitors and finding synergistic drug combinations. Sci Rep. 2018;8:3010. https://doi.org/10.1038/s41598-017-14900-0 .
doi: 10.1038/s41598-017-14900-0
pubmed: 29445088
pmcid: 5813176
Welch DR, Hurst DR. Defining the hallmarks of Metastasis. Cancer Res. 2019;79:3011–27. https://doi.org/10.1158/0008-5472.CAN-19-0458 .
doi: 10.1158/0008-5472.CAN-19-0458
pubmed: 31053634
pmcid: 6571042
Ford CA, Petrova S, Pound JD, Voss JJ, Melville L, Paterson M, et al. Oncogenic properties of apoptotic Tumor cells in aggressive B cell Lymphoma. Curr Biol. 2015;25:577–88. https://doi.org/10.1016/j.cub.2014.12.059 .
doi: 10.1016/j.cub.2014.12.059
pubmed: 25702581
pmcid: 4353688
Zhao Y, Lu T, Song Y, Wen Y, Deng Z, Fan J, et al. Cancer cells enter an adaptive persistence to survive Radiotherapy and Repopulate Tumor. Adv Sci (Weinh). 2023;10:e2204177. https://doi.org/10.1002/advs.202204177 .
doi: 10.1002/advs.202204177
pubmed: 36658726
Mazzeschi M, Sgarzi M, Romaniello D, Gelfo V, Cavallo C, Ambrosi F, et al. The autocrine loop of ALK receptor and ALKAL2 ligand is an actionable target in consensus molecular subtype 1 colon Cancer. J Exp Clin Cancer Res. 2022;41:113. https://doi.org/10.1186/s13046-022-02309-1 .
doi: 10.1186/s13046-022-02309-1
pubmed: 35351152
pmcid: 8962179
Ciocca DR, Arrigo AP, Calderwood SK. Heat shock proteins and heat shock factor 1 in carcinogenesis and Tumor development: an update. Arch Toxicol. 2013;87:19–48. https://doi.org/10.1007/s00204-012-0918-z .
doi: 10.1007/s00204-012-0918-z
pubmed: 22885793
Mambula SS, Calderwood SK. Heat shock protein 70 is secreted from Tumor cells by a nonclassical pathway involving lysosomal endosomes. J Immunol. 2006;177:7849–57. https://doi.org/10.4049/jimmunol.177.11.7849 .
doi: 10.4049/jimmunol.177.11.7849
pubmed: 17114456
Galluzzi L, Kepp O. Kroemer GCaspase-3 and prostaglandins signal for Tumor regrowth in cancer therapy. Oncogene. 2012;31:2805–8. https://doi.org/10.1038/onc.2011.459 .
doi: 10.1038/onc.2011.459
pubmed: 21963852
Linder M, Pogge von Strandmann E. The role of Extracellular HSP70 in the function of Tumor-Associated Immune cells. Cancers (Basel). 2021;13:4721. https://doi.org/10.3390/cancers13184721 .
doi: 10.3390/cancers13184721
pubmed: 34572948
Minnaar CA, Szasz A. Forcing the Antitumor effects of HSPs using a Modulated Electric Field. Cells. 2022;11:1838. https://doi.org/10.3390/cells11111838 .
doi: 10.3390/cells11111838
pubmed: 35681533
pmcid: 9180583
Radogna F, Diederich M. Stress-induced cellular responses in immunogenic cell death: implications for cancer immunotherapy. Biochem Pharmacol. 2018;153:12–23. https://doi.org/10.1016/j.bcp.2018.02.006 .
doi: 10.1016/j.bcp.2018.02.006
pubmed: 29438676
Recasens A, Munoz L. Targeting Cancer Cell Dormancy. Trends Pharmacol Sci. 2019;40:128–41. https://doi.org/10.1016/j.tips.2018.12.004 .
doi: 10.1016/j.tips.2018.12.004
pubmed: 30612715
Rodina A, Wang T, Yan P, Gomes ED, Dunphy MP, Pillarsetty N, et al. The epichaperome is an integrated chaperome network that facilitates tumour survival. Nature. 2016;20538:397–401. https://doi.org/10.1038/nature19807 .
doi: 10.1038/nature19807
Ryu SW, Stewart R, Pectol DC, Ender NA, Wimalarathne O, Lee JH, et al. Proteome-wide identification of HSP70/HSC70 chaperone clients in human cells. PLoS Biol. 2020;18:e3000606. https://doi.org/10.1371/journal.pbio.3000606 .
doi: 10.1371/journal.pbio.3000606
pubmed: 32687490
pmcid: 7392334
Mao H, Li F, Ruchalski K, Mosser DD, Schwartz JH, Wang Y, Borkan SC. hsp72 inhibits focal adhesion kinase degradation in ATP-depleted renal epithelial cells. J Biol Chem. 2003;278:18214–20. https://doi.org/10.1074/jbc.M300126200 .
doi: 10.1074/jbc.M300126200
pubmed: 12611892
Komarova EY, Afanasyeva EA, Bulatova MM, Cheetham ME, Margulis BA, Guzhova IV. Downstream caspases are novel targets for the antiapoptotic activity of the molecular chaperone hsp70. Cell Stress Chaperones. 2004;9:265–75. https://doi.org/10.1379/csc-27r1.1 .
doi: 10.1379/csc-27r1.1
pubmed: 15544164
pmcid: 1065285
Zhang H, Guo Z, Guo Y, Wang Z, Tang Y, Song T, Zhang Z. Bim transfer between bcl-2-like protein and Hsp70 underlines Bcl-2/Hsp70 crosstalk to regulate apoptosis. Biochem Pharmacol. 2021;190:114660. https://doi.org/10.1016/j.bcp.2021.114660 .
doi: 10.1016/j.bcp.2021.114660
pubmed: 34153292
Muth C, Rubner Y, Semrau S, Rühle PF, Frey B, Strnad A, Buslei R, Fietkau R, Gaipl US. Primary Glioblastoma Multiforme tumors and recurrence: comparative analysis of the danger signals HMGB1, HSP70, and calreticulin. Strahlenther Onkol. 2016;192:146–55. https://doi.org/10.1007/s00066-015-0926-z .
doi: 10.1007/s00066-015-0926-z
pubmed: 26646311
Lai W, Li X, Kong Q, Chen H, Li Y, Xu LH, Fang J. Extracellular HMGB1 interacts with RAGE and promotes chemoresistance in acute Leukemia cells. Cancer Cell Int. 2021;21:700. https://doi.org/10.1186/s12935-021-02387-9 .
doi: 10.1186/s12935-021-02387-9
pubmed: 34933679
pmcid: 8693501
Ye C, Li H, Li Y, Zhang Y, Liu G, Mi H, Li H, Xiao Q, Niu L, Yu X. Hypoxia-induced HMGB1 promotes glioma stem cells self-renewal and tumorigenicity via RAGE. iScience. 2022;25:104872. https://doi.org/10.1016/j.isci.2022.104872 .
doi: 10.1016/j.isci.2022.104872
pubmed: 36034219
pmcid: 9399482
Zhou Y, Liu X, Zhang W, Xu Y, Zhang Q, Xiong S, Tang H, Luo B. HMGB1 released from dead Tumor cells after insufficient radiofrequency ablation promotes progression of HCC residual Tumor via ERK1/2 pathway. Int J Hyperthermia. 2023;40:2174709. https://doi.org/10.1080/02656736.2023.2174709 .
doi: 10.1080/02656736.2023.2174709
pubmed: 36755436
Singh A, Gupta N, Khandakar H, Kaushal S, Seth A, Pandey RM, Sharma A. Autophagy-associated HMGB-1 as a novel potential circulating non-invasive diagnostic marker for detection of Urothelial Carcinoma of bladder. Mol Cell Biochem. 2022;477:493–505. https://doi.org/10.1007/s11010-021-04299-8 .
doi: 10.1007/s11010-021-04299-8
pubmed: 34796446
Zhou Y, Liu X, Zhang W, Xu Y, Zhang Q, Xiong S, Tang H, Luo B (2023) HMGB1 released from dead tumor cells after insufficient radiofrequency ablation promotes progression of HCC residual tumor via ERK1/2 pathway. Int J Hyperthermia 40:2174709. https://doi.org/10.1080/02656736.2023.2174709
doi: 10.1080/02656736.2023.2174709
pubmed: 36755436
Zhao M, Zhang Y, Jiang Y, Wang K, Wang X, Zhou D, Wang Y, Yu R, Zhou X. YAP promotes autophagy and progression of gliomas via upregulating HMGB1. J Exp Clin Cancer Res. 2021;40:99. https://doi.org/10.1186/s13046-021-01897-8 .
doi: 10.1186/s13046-021-01897-8
pubmed: 33726796
pmcid: 7968184
Jung AR, Kim GE, Kim MY, Ha US, Hong SH, Lee JY, Kim SW, Park YH. HMGB1 promotes Tumor progression and invasion through HMGB1/TNFR1/NF-κB axis in castration-resistant Prostate cancer. Am J Cancer Res. 2021;11:2215–27.
pubmed: 34094679
pmcid: 8167672
Zhu L, Ren S, Daniels MJ, Qiu W, Song L, You T, Wang D, Wang Z. Exogenous HMGB1 promotes the proliferation and Metastasis of Pancreatic Cancer cells. Front Med (Lausanne). 2021;8:756988. https://doi.org/10.3389/fmed.2021.756988 .
doi: 10.3389/fmed.2021.756988
pubmed: 34805222
Youn JH, Shin JS. Nucleocytoplasmic shuttling of HMGB1 is regulated by phosphorylation that redirects it toward secretion. J Immunol. 2006;177:7889–97. https://doi.org/10.4049/jimmunol.177.11.7889 .
doi: 10.4049/jimmunol.177.11.7889
pubmed: 17114460
Bonaldi T, Talamo F, Scaffidi P, Ferrera D, Porto A, Bachi A, Rubartelli A, Agresti A, Bianchi ME. Monocytic cells hyperacetylate chromatin protein HMGB1 to redirect it towards secretion. EMBO J. 2003;22:5551–60. https://doi.org/10.1093/emboj/cdg516 .
doi: 10.1093/emboj/cdg516
pubmed: 14532127
pmcid: 213771
Kim YH, Kwak MS, Park JB, Lee SA, Choi JE, Cho HS, Shin JS (2016) N-linked glycosylation plays a crucial role in the secretion of HMGB1. J Cell Sci 129:29–38. https://doi.org/10.1242/jcs.176412
doi: 10.1242/jcs.176412
pubmed: 26567221
Shao H, Li X, Moses MA, Gilbert LA, Kalyanaraman C, Young ZT, Chernova M, et al. Exploration of Benzothiazole Rhodacyanines as Allosteric inhibitors of protein-protein interactions with heat shock protein 70 (Hsp70). J Med Chem. 2018;61:6163–77. https://doi.org/10.1021/acs.jmedchem.8b00583 .
doi: 10.1021/acs.jmedchem.8b00583
pubmed: 29953808
pmcid: 6104643